Human Biodistribution and Radiation Dosimetry of the Targeting Fibroblast Growth Factor Receptor 1-Positive Tumors Tracer [ 68 Ga]Ga-DOTA-FGFR1-Peptide
Cancer Biotherapy and Radiopharmaceuticals · 2024
DOI: 10.1089/cbr.2024.0073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Huiqing Yuan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 1, Gallium Radioisotopes, Radiopharmaceuticals, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective: [ 68 Ga]Ga-DOTA-FGFR1-peptide is a novel positron emission tomography (PET) radiotracer targeting fibroblast growth factor receptor 1 (FGFR1). This study evaluated the safety, biodistribution, radiation dosimetry, and imaging potential of [ 68 Ga]Ga-DOTA-FGFR1-peptide.
Methods
The FGFR1-targeting peptide DOTA-(PEG2)-KAEWKSLGEEAWHSK was synthesized by manual solid-phase peptide synthesis with high-performance liquid chromatography purification, and labeled with 68 Ga with DOTA as chelating agent. We recruited 14 participants and calculated the radiation dose of 4 of these pathologically confirmed nontumor subjects using OLINDA/EXM 2.2.0 software. At the same time, the imaging potential in 10 of these lung cancer patients was evaluated.
Results
The biodistribution of [ 68 Ga]Ga-DOTA-FGFR1-peptide in 4 subjects showed the highest uptake in the bladder and kidney. Dosimetry analysis indicated that the bladder wall received the highest effective dose (3.73E-02 mSv/MBq), followed by the lungs (2.36E-03 mSv/MBq) and red bone marrow (2.09E-03 mSv/MBq). No normal organs were found to have excess specific absorbed doses. The average systemic effective dose was 4.97E-02 mSv/MBq. The primary and metastatic tumor lesions were clearly visible on PET/computed tomography (CT) images in 10 patients.
Conclusion
Our results indicate that [ 68 Ga]Ga-DOTA-FGFR1-peptide has a good dosimetry profile and can be used safely in humans, and it has significant potential value for clinical PET/CT imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China.
ORCID-Profile: Xinming Zhao
Zitieren
APA
Yuan, H., Chen, X., Zhao, M., Zhao, X., Chen, X., Han, J., Zhang, Z., Zhang, J., Wang, J., Dai, M., & Liu, Y. (2024). Human Biodistribution and Radiation Dosimetry of the Targeting Fibroblast Growth Factor Receptor 1-Positive Tumors Tracer [ 68 Ga]Ga-DOTA-FGFR1-Peptide. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2024.0073
Vancouver
Yuan H, Chen X, Zhao M, Zhao X, Chen X, Han J, et al. Human Biodistribution and Radiation Dosimetry of the Targeting Fibroblast Growth Factor Receptor 1-Positive Tumors Tracer [ 68 Ga]Ga-DOTA-FGFR1-Peptide. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2024.0073
BibTeX
@article{Yuan2024,
author = {Yuan, Huiqing and Chen, Xiaoshan and Zhao, Mengmeng and Zhao, Xinming and Chen, Xiaolin and Han, Jingya and Zhang, Zhaoqi and Zhang, Jingmian and Wang, Jianfang and Dai, Meng and Liu, Yunuan},
title = {Human Biodistribution and Radiation Dosimetry of the Targeting Fibroblast Growth Factor Receptor 1-Positive Tumors Tracer [ 68 Ga]Ga-DOTA-FGFR1-Peptide},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
doi = {10.1089/cbr.2024.0073}
}
EUVIMED